SunTech: International growth through acquisitions

The number of people living with hypertension has doubled globally since 1990 and today one in three people are affected by the condition.

Ambulatory Blood Pressure Monitoring (ABPM) allows healthcare providers to assess blood pressure during a patient’s daily routine, instead of when sitting nervously in the doctor’s office. This provides more accurate readings over a longer period, enabling clinicians to make better informed decisions. National health authorities across the world are starting to use blood pressure measurements to catch potential cardiovascular diseases at an earlier stage, so accuracy is critical. 

As a market leader in motion tolerant blood pressure measurement, SunTech’s technology provides valuable diagnostic information that other monitoring systems are incapable of measuring. SunTech had been looking to expand into Europe and Meditech was the natural choice. Founded in 1990 in Budapest, Hungary, Meditech has established itself as a European market leader in ABPM. SunTech’s relationship with Meditech goes back many years, with Meditech manufacturing SunTech’s first ABPM product, the Oscar. 

Meditech has a deep knowledge of blood pressure monitoring and additional expertise in the measurement of heart activity. Their specialist regulatory knowledge of the European market will also help SunTech expand its international reach and deepen its application knowledge. SunTech, with Halma’s help, can also accelerate Meditech’s growth with expansion of global market access and new innovations. 

"As we have grown to know the team at Meditech, we were highly impressed with their talented leadership, and we believe that by acquiring them we have added significant commercial, R&D, operational and regulatory capabilities to the combined group.”

Rob Sweitzer, President, SunTech Medical

Together, SunTech and Meditech will use their expertise in ABPM to bring new innovations to the market, improving the diagnosis and management of hypertension worldwide. Their combined impact is helping towards a key World Health Organization target: to reduce the global prevalence of hypertension by 33% between 2010 and 2030.

animated svg for hover